^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:pictilisib (GDC-0941) (PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

    Excerpt:
    ...the GDC-0941/MEK inhibitor combination showed the strongest combination effects, and was particularly effective in cell lines with EGFR activation, PIK3CA mutations, or KRAS mutations...
    Secondary therapy:
    MEK Inhibitor
    DOI:
    10.1158/1078-0432.CCR-12-2347